Flexion Therapeutics (NASDAQ:FLXN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, January 9th.
According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “
A number of other equities analysts have also recently issued reports on FLXN. Royal Bank of Canada set a $44.00 target price on Flexion Therapeutics and gave the stock a “buy” rating in a report on Monday, September 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target on shares of Flexion Therapeutics in a research report on Sunday, September 17th. Northland Securities reaffirmed a “buy” rating and set a $40.00 price target on shares of Flexion Therapeutics in a research report on Wednesday, October 4th. Wells Fargo & Co set a $39.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a research report on Friday, October 6th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $37.00 price target (up previously from $35.00) on shares of Flexion Therapeutics in a research report on Monday, October 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $99.11.
Flexion Therapeutics (FLXN) opened at $22.31 on Tuesday. The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics has a 1-year low of $16.51 and a 1-year high of $32.25. The stock has a market capitalization of $852.18, a PE ratio of -6.34 and a beta of 1.14.
Flexion Therapeutics (NASDAQ:FLXN) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.09). sell-side analysts expect that Flexion Therapeutics will post -3.84 EPS for the current year.
In other news, insider Neil Bodick bought 2,700 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were acquired at an average price of $24.49 per share, with a total value of $66,123.00. Following the transaction, the insider now owns 64,605 shares in the company, valued at $1,582,176.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael D. Clayman bought 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $23.60 per share, for a total transaction of $118,000.00. Following the transaction, the insider now owns 35,395 shares in the company, valued at approximately $835,322. The disclosure for this purchase can be found here. 15.98% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. Fiduciary Trust Co. acquired a new stake in Flexion Therapeutics in the 2nd quarter valued at approximately $101,000. Advisor Group Inc. grew its stake in Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 3,500 shares in the last quarter. SG Americas Securities LLC bought a new position in Flexion Therapeutics in the third quarter valued at approximately $135,000. IFP Advisors Inc grew its stake in Flexion Therapeutics by 58.1% in the third quarter. IFP Advisors Inc now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $194,000 after purchasing an additional 2,950 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new position in Flexion Therapeutics in the third quarter valued at approximately $235,000. 72.78% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Flexion Therapeutics (NASDAQ:FLXN) Lifted to Hold at Zacks Investment Research” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/02/flexion-therapeutics-flxn-upgraded-by-zacks-investment-research-to-hold.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.